Atibuclimab

Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist.
Read more
€0.00 (tax incl.)
Reference:
HY-P99008
Product Details
HY-P99008

Data sheet

Size
Multiple sizes
Reactivity
Others
Application
COVID-19-immunoregulation
CAS
2417175-94-9

Menu

Settings